Thomas Mulligan, MD
Ophthalmology · Seattle, WANPI 1952467573
Payments from drug & device makers
What this record shows
This record is dominated by charitable contributions: $1,091 of the $1,362 with a category attached, or 80.1%. Microsurgical Technology, Inc. accounts for 80.1% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $562, more than ten times the $12 reported in 2019.
Across 9 payments — averaging $151.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Microsurgical Technology, Inc.$1K
- Glaukos Corporation$159
- Carl Zeiss Meditec AG$58
- Johnson & Johnson Surgical Vision, Inc.$53
What the payments were for
- Food & beverage$21316%
- Gifts$584%
- Charitable contribution$1,09180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Microsurgical Technology, Inc. | 2 | $1,091 |
| Glaukos Corporation | 1 | $159 |
| Carl Zeiss Meditec AG | 3 | $58 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $53 |
How this compares
$1,362 in reported general payments places this provider in the 60th percentile of 428 ophthalmology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 28 | $26,496 |
| Difluprednate | 68 | $5,661 |
| Latanoprost | 348 | $3,906 |
| Timolol Maleate | 220 | $2,537 |
| Doxycycline Hyclate | 52 | $1,904 |
| Cyclosporine | 15 | $1,696 |
| Prednisolone Acetate | 42 | $1,550 |
| Fluorometholone | 17 | $1,122 |
| Doxycycline Monohydrate | 42 | $991 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 57 | $706 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 51 | $516 |
| ErythromycinErythromycin Base | 31 | $362 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $294 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Seattle
- Laura PerimanSeattle$1.7M
- Sheldon CowenSeattle$560K
- Jennifer ChaoSeattle$188K
- Debarshi MustafiSeattle$85K
- Michelle CabreraSeattle$75K
- Paul GriggsSeattle$62K
- Lisa Olmos de KooSeattle$50K
- Kathryn PeppleSeattle$29K
- Yewlin CheeSeattle$23K
- Miel SundararajanSeattle$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.